Log In
Print this Print this

Kadcyla, ado-trastuzumab emtansine, trastuzumab emtansine (T-DM1) (RG3502)

Also known as: trastuzumab-DM1

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionHumanized mAb against epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu) linked to ImmunoGen's DM1 cytotoxic agent
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today